IL-38 in modulating hyperlipidemia and its related cardiovascular diseases

Min Lai,Hua Peng,Xijie Wu,Xiang Chen,Bin Wang,Xin Su
DOI: https://doi.org/10.1016/j.intimp.2022.108876
IF: 5.714
2022-01-01
International Immunopharmacology
Abstract:•IL-38 has been shown to play an important role in modulating the pathogenesis of hyperlipidemia.•IL-38 inhibits the CD4 positive T lymphocyte into Th-17 which enhance the immunosuppressive activity of the T-reg.•IL-38 suppresses the expression of inflammatory factors through the MAPK signaling pathway.•IL-38 may be a potential disease biomarker and a new therapeutic target for hyperlipidemia.
What problem does this paper attempt to address?